Beware at the pharmacy counter: Your insurance company could be in cahoots with a pharmacy benefit manager — and the negotiations that go on between them are trade secrets.
Category: prescription drugs
How Many Medicare Part D Enrollees Had High Out-of-Pocket Drug Costs in 2017?
The Medicare Part D prescription drug benefit has helped improve the affordability of medications for people with Medicare. Yet Part D enrollees can face relatively high out-of-pocket costs because the Part D benefit does not have a hard cap on out-of-…
Data Note: Americans’ Challenges with Health Care Costs
This data note summarizes our most recent polling on the public’s experiences with and worries about health care costs, and it highlights where Americans place costs on their list of health care issues for the government to address and for political c…
Data Note: Americans’ Challenges with Health Care Costs
This data note summarizes our most recent polling on the public’s experiences with and worries about health care costs, and it highlights where Americans place costs on their list of health care issues for the government to address and for political c…
FDA Overlooked Red Flags In Drugmaker’s Testing of New Depression Medicine
In March, a chemical cousin of the anesthetic and club drug ketamine was approved for the treatment of patients with intractable depression. But critics say studies presented to the FDA provided at best modest evidence it worked and did not include information about the safety of the drug, Spravato, for long-term use.
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don’t have to.
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don’t have to.
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don’t have to.
New Analysis Compares Prescription Drug Spending and Use Across Large Employer Plans, Medicare, and Medicaid
As policymakers debate how to address the high cost of prescription drugs, a new KFF analysis compares data on prescription drug spending and use across large employer plans, Medicare Part D and Medicaid, and provides context for policy discussions abo…
How Does Prescription Drug Spending and Use Compare Across Large Employer Plans, Medicare Part D, and Medicaid?
Prescription drug costs are a pressing concern for both consumers and policymakers. This analysis compares prescription drug spending and use in large private employer plans, Medicare Part D, and Medicaid, based primarily on claims data by payer, which…
